A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
- Conditions
- Non-Small-Cell Lung AdenocarcinomaNon-small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage IVNon-small Cell Lung Cancer Metastatic
- Interventions
- Registration Number
- NCT01798485
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Brief Summary
The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of patients with advanced non-small cell lung cancer.
- Detailed Description
Preliminary signals of clinical activity of ganetespib as a single agent have been observed in patients with advanced NSCLC. A Phase 2b/3 Study (9090-08) was initiated to evaluate the safety and activity of ganetespib in combination with docetaxel vs. docetaxel alone in NSCLC. Study 9090-08 is ongoing. Results from an interim analysis show that the combination has been well tolerated and an encouraging improvement in efficacy, including overall survival (OS) has been observed.
Update: An independent data monitoring committee (DMC) was established to review accumulating unblinded safety data, and efficacy data at two specified Interim Analyses. The DMC monitored the conduct of the trial (including the accrual/retention of patients) and reviewed the risks and benefits. The study was stopped after the first Interim Analysis due to futility.
The efficacy portion of this report is based on a 05 October 2015 data cut after the number of protocol-defined death events (336) for the first interim analysis had been achieved. The safety portion is based on the final database locked on 23 December 2015.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 696
- Advanced Stage IIIB or IV non-small-cell lung cancer (NSCLC)
- Eastern Oncology Cooperative Group (ECOG) Performance Status 0 or 1
- Prior therapy defined as 1 prior systemic therapy for advanced disease
- Documented disease progression during or following most first line therapy for advanced disease
- Adequate hematologic, hepatic, renal function
- Epidermal growth factor receptor (EGFR) mutations
- Anaplastic lymphoma kinase (ALK) translocations
- Predominantly squamous, adenosquamous or unclear histologic type
- Active or untreated central nervous system (CNS) metastases
- Active malignancies other than NSCLC within the last 5 years with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin
- Serious cardiac illness or medical conditions
- Pregnant or lactating women
- Uncontrolled intercurrent illness
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Ganetespib and Docetaxel Ganetespib Ganetespib (150 mg/m\^2) and docetaxel (75 mg/m\^2) were administered as separate 1-hour IV infusions on Day 1 of each 3-week treatment cycle. Administration of ganetespib preceded the administration of docetaxel. Ganetespib was administered again on Day 15 of each cycle. Ganetespib and Docetaxel Docetaxel Ganetespib (150 mg/m\^2) and docetaxel (75 mg/m\^2) were administered as separate 1-hour IV infusions on Day 1 of each 3-week treatment cycle. Administration of ganetespib preceded the administration of docetaxel. Ganetespib was administered again on Day 15 of each cycle. Docetaxel Docetaxel Docetaxel (75 mg/m\^2) was administered on Day 1 of a 3-week treatment cycle by 1-hour IV infusion.
- Primary Outcome Measures
Name Time Method Overall Survival as of 19 October 2015 up to 36 months Overall survival (OS) was measured from the date of randomization to the date of death from any cause.
- Secondary Outcome Measures
Name Time Method Overall Survival (OS) In Participants With an Elevated Screening Lactate Dehydrogenase (eLDH) as of 19 October 2015 up to 36 months OS was measured from the date of randomization to the date of death from any cause. Elevated LDH includes values above the upper limit of normal.
Percentage of Participants With Progressive Disease Due to Any New Metastatic Lesion as of 19 October 2015 up to 36 months Progressive disease was due to either new metastatic lesions only or new metastatic lesions and target tumor growth.
Progression-free Survival (PFS) as of 19 October 2015 up to 36 months The progression-free interval is the interval from the date of randomization until tumor progression per modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1), clinical progression, or death from any cause in the absence of progressive disease, whichever occurs first. Data represents the investigator's assessment.
Progressive Disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.Objective Response Rate (ORR) as of 19 October 2015 up to 36 months Percentage of participants whose best overall response, as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), was either a complete response (CR) or a partial response (PR).
CR was defined as the disappearance (or normalization) of all target lesions. PR was defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters.Disease Control Rate (DCR) as of 19 October 2015 up to 36 months Percentage of participants whose best overall response, as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), was either a complete response (CR), a partial response (PR), or stable disease (SD).
CR was defined as the disappearance (or normalization) of all target lesions. PR was defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters.
SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum of diameters while on study. For participants with a best response of SD, duration of SD must be for at least 6 weeks or 12 weeks.Kaplan-Meier Estimate of Duration of Response (DOR) as of 19 October 2015 up to 36 months Only participants who achieved a confirmed response (complete response (CR) or partial response (PR)) were included in the DOR analysis.
CR was defined as the disappearance (or normalization) of all target lesions.
PR was defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters.Progression Free Survival (PFS) in Participants With an Elevated Screening Lactate Dehydrogenase (eLDH) as of 19 October 2015 up to 36 months The progression-free interval is the interval from the date of randomization until tumor progression per modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1), clinical progression, or death from any cause in the absence of progressive disease, whichever occurs first. Data represents the investigator's assessment.
Progressive Disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Elevated LDH includes values above the upper limit of normal.Objective Response Rate (ORR) in Participants With an Elevated Screening Lactate Dehydrogenase (eLDH) as of 19 October 2015 up to 36 months Percentage of participants whose best overall response, as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), was either a complete response (CR) or a partial response (PR).
CR was defined as the disappearance (or normalization) of all target lesions.
PR was defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters.
Elevated LDH includes values above the upper limit of normal.
This study stopped prematurely due to futility and development of this product ceased. The sponsor made a decision at that time to not analyze this outcome. The sponsor no longer has staff or capabilities for further analysis.Disease Control Rate (DCR) in Participants With an Elevated Screening Lactate Dehydrogenase (eLDH) as of 19 October 2015 up to 36 months Percentage of participants whose best overall response, as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), was a complete response (CR), a partial response (PR), or stable disease (SD).
CR was defined as the disappearance (or normalization) of all target lesions.
PR was defined as \<=30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters.
SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum of diameters while on study. The duration of SD must be for at least 6 weeks or 12 weeks.
Elevated LDH includes values above the upper limit of normal.
This study stopped prematurely due to futility and development of this product ceased. The sponsor made a decision at that time to not analyze this outcome. The sponsor no longer has staff or capabilities for further analysis.Kaplan-Meier Estimate for Time to Emergence of New Metastatic Lesion (TNL) as of 19 October 2015 up to 36 months TNL was defined as time from the randomization date to the first day of radiological progression that included new metastatic lesions. Participants with no new metastatic lesions were censored at the date of the most recent radiological assessment.
Participants With Treatment-Emergent Adverse Events as of 23 December 2015 up to 36 months Treatment-emergent adverse events (AEs) were defined as AEs that occurred from the time of first dose through 30 days after the last dose of study medication. The Investigator graded the severity of AEs according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) criteria:
Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death A Serious AE (SAE) is defined as any AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or constitutes an important medical event.Patient-Reported Symptom Improvement as Measured by the Functional Assessment of Cancer Therapy - Lung (FACT-L) Version 4 Test Day 1 (pre-treatment), Day 63 (Cycle 3 Day 1), Day 105 (Cycle 5 Day 1) and end of trial The FACT-L contains 4 general subscales and a Lung Cancer Subscale (LCS). General subscales include: Physical Well-Being (PWB), Social/ Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). The LCS assesses symptoms commonly reported by lung cancer patients (e.g., shortness of breath, weight loss, and tightness in the chest). The FACT-L total score ranges from 0 to 136, higher scores represent better QOL.
Data were not summarized due to the early termination of the study due to futility.Patient-Reported Quality of Life as Measured by the European Quality Of Life - Five Dimensions - Three Levels (EQ-5D-3L) Survey Day 1 (pre-treatment), Day 63 (Cycle 3 Day 1), Day 105 (Cycle 5 Day 1) and end of trial The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. An overall EQ-5D-3L index was calculated (see EuroQoL website, http://www.euroqol.org/eq-5d-products/eq-5d-3l.html), with an index of 1.0 representing full health and and "0" represents dead, with some health states being worse than dead (\<"0").
This study stopped prematurely due to futility and development of this product ceased. The sponsor made a decision at that time to not analyze this outcome. The sponsor no longer has staff or capabilities for further analysis.
Trial Locations
- Locations (203)
VA Greater Los Angeles Healthcare System
🇺🇸Los Angeles, California, United States
Ronald Reagan UCLA Medical Center
🇺🇸Los Angeles, California, United States
University of Pittsburgh Medical Center
🇺🇸Pittsburgh, Pennsylvania, United States
The John R Marsh Cancer Center
🇺🇸Hagerstown, Maryland, United States
Synta Pharmaceuticals Investigative Site
🇺🇦Kharkiv, Ukraine
Cancer Care Centers Of South Texas
🇺🇸San Antonio, Texas, United States
Cancer Care Centers of South Texas
🇺🇸San Antonio, Texas, United States
Universitaetsklinikum des Saarlandes
🇩🇪Homburg, Saarland, Germany
Krankenhaus Der Barmherzigen Schwestern
🇦🇹Linz, Oberösterreich, Austria
Clinical Hospital Mostar
🇧🇦Mostar, Bosnia and Herzegovina
Chi creteil
🇫🇷Creteil, Val-de-Marne, France
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Universiaetsklinikum Ulm
🇩🇪Ulm, Baden-Württemberg, Germany
Centre Hosptalier De Villefranche-Sur-Saone
🇫🇷Villefranche Sur Saone, Rhône, France
Sozialmedizinisches Zentrum Baumgartner Höhe
🇦🇹Wien, Austria
Centre D'Oncologie Du Pays Basque
🇫🇷Bayonne, Pyrénées-Atlantiques, France
Presidio Ospedaliero Centrale Belcolle, AUSL Viterbo
🇮🇹Viterbo, Lazio, Italy
Fakultni nemocnice Olomouc
🇨🇿Olomouc, Czech Republic
Szpital Wojewodzki w Lomzy im. Kardynala S. Wyszynskiego
🇵🇱Lomza, Podlaskie, Poland
Institutul Regional de Oncologie Iasi
🇷🇴Iasi, Romania
Institutul Oncologic "Prof. Dr. Alex. Trestioreanu"
🇷🇴Bucharest, Romania
Spitalul Universitar de Urgenta Bucuresti
🇷🇴Bucharest, Romania
Centrul de Oncologie Sf. Nectarie
🇷🇴Craiova, Romania
Clinical Center Kragujevac
🇷🇸Kragujevac, Šumadijski okrug, Serbia
Henry Ford Hospital
🇺🇸Detroit, Michigan, United States
Istituto Europeo di Oncologia, Istituto di Ricovero e Cura a
🇮🇹Milano, Italy
Arizona Oncology Associates PC- NAHOA
🇺🇸Flagstaff, Arizona, United States
Arizona Oncology Associates, PC- NAHOA
🇺🇸Prescott Valley, Arizona, United States
Northern Arizona Hematology & Oncology Associates
🇺🇸Sedona, Arizona, United States
Pacific Cancer Medical Center, Inc
🇺🇸Anaheim, California, United States
Comprehensive Blood & Cancer Center
🇺🇸Bakersfield, California, United States
Loma Linda University Cancer Center
🇺🇸Loma Linda, California, United States
St. Joseph Hospital, Center for Cancer Prevention and Treatment
🇺🇸Orange, California, United States
City of Hope- South Pasadena
🇺🇸South Pasadena, California, United States
Medical Oncology Hematology Consultants, PA
🇺🇸Newark, Delaware, United States
Baptist Health Medical Group Oncology, LLC
🇺🇸Miami, Florida, United States
Memorial Regional Hospital
🇺🇸Hollywood, Florida, United States
University of Miami Health System Sylvester at Deerfield Beach
🇺🇸Deerfield Beach, Florida, United States
Emory University - Winship Cancer Institute
🇺🇸Atlanta, Georgia, United States
AAMC Oncology and Hematology
🇺🇸Annapolis, Maryland, United States
Palm Beach Cancer Institute
🇺🇸West Palm Beach, Florida, United States
Northwest Georgia Oncology Centers, PC
🇺🇸Marietta, Georgia, United States
Saint Anthony Medical Center
🇺🇸Rockford, Illinois, United States
Fort Wayne Medical Oncology and Hematology Inc
🇺🇸Fort Wayne, Indiana, United States
St. Luke's Hospital Duluth
🇺🇸Duluth, Minnesota, United States
Clinical Research Alliance
🇺🇸Lake Success, New York, United States
Renown Regional Medical Center
🇺🇸Reno, Nevada, United States
Hackensack University Medical Center - John Theurer Cancer Center
🇺🇸Hackensack, New Jersey, United States
Texas Oncology, PA
🇺🇸Dallas, Texas, United States
Simmons Comprehensive Cancer Center
🇺🇸Dallas, Texas, United States
Tulsa Cancer Institute, PLLC
🇺🇸Tulsa, Oklahoma, United States
Erlanger Institute for Clinical Research
🇺🇸Chattanooga, Tennessee, United States
Rapid City Regional Hospital
🇺🇸Rapid City, South Dakota, United States
Prairie Lakes Healthcare System
🇺🇸Watertown, South Dakota, United States
Associates In Oncology and Hematology
🇺🇸Chattanooga, Tennessee, United States
Texas Oncology-Arlington North
🇺🇸Arlington, Texas, United States
Thompson Cancer Survival Center
🇺🇸Knoxville, Tennessee, United States
Texas Oncology - Arlington South
🇺🇸Arlington, Texas, United States
Millennium Oncology
🇺🇸Houston, Texas, United States
Green Bay Oncology, Ltd. - St. Mary's Site
🇺🇸Green Bay, Wisconsin, United States
Northwest Medical Specialties, PLLC
🇺🇸Tacoma, Washington, United States
Mary Babb Cancer Center
🇺🇸Morgantown, West Virginia, United States
Otto Wagner Spital
🇦🇹Wien, Austria
Allgemeines Krankenhaus Linz
🇦🇹Linz, Austria
Bezirkskrankenhaus Kufstein [Onkologie]
🇦🇹Kufstein, Tirol, Austria
Grand Hôpital de Charleroi - Site Notre-Dame
🇧🇪Charleroi, Hainaut, Belgium
CHU Dinant Godinne UCL Namur
🇧🇪Yvoir, Namur, Belgium
Algemeen Stedelijk Ziekenhuis - Campus Aalst
🇧🇪Roeselaere, West-Vlaanderen, Belgium
INDC Entité Jolimontoise - Polyclinique de Jolimont
🇧🇪Haine St. Paul, Hainaut, Belgium
CHR de la Citadelle - Site Citadelle
🇧🇪Liège, Belgium
Clinical Centre Banja Luka
🇧🇦Banja Luka, Republika Srpska, Bosnia and Herzegovina
University Clinical Center Tuzla
🇧🇦Tuzla, Bosnia and Herzegovina
University Clinical Centre Sarajevo
🇧🇦Sarajevo, Bosnia and Herzegovina
Clinical Center University of Sarajevo, Clinic of Oncology
🇧🇦Sarajevo, Bosnia and Herzegovina
Kantonalna bolnica Zenica
🇧🇦Zenica, Bosnia and Herzegovina
Princess Margaret Hospital
🇨🇦Toronto, Ontario, Canada
Groupe Hospitalier Cochin
🇫🇷Paris, France
University Hospital Center Zagreb
ðŸ‡ðŸ‡·Zagreb, Grad Zagreb, Croatia
Centre Léon Bérard
🇫🇷Lyon, France
Mc Gill University-MUHC
🇨🇦Montreal, Quebec, Canada
Centre Hospitalier Universitaire de Rennes - Hopital d
🇫🇷Rennes, France
Nemocnice Na Bulovce
🇨🇿Prague, Czech Republic
CHI des Alpes du Sud
🇫🇷Gap, Hautes-Alpes, France
Policlinico S.Orsola Malpighi, AOU di Bologna
🇮🇹Bologna, Italy
Universitätsklinikum Freiburg
🇩🇪Freiburg, Baden-Württemberg, Germany
Hôpital Charles Nicolle
🇫🇷Rouen, France
Asklepios Fachklinik München-Gauting
🇩🇪Gauting, Bayern, Germany
Schwarzwald-Baar-Klinikum
🇩🇪Villingen-Schwenningen, Baden-Württemberg, Germany
Klinikum Offenbach GmbH
🇩🇪Offenbach, Germany
Pneumologisches Forschungsinstitut an der Lungenclinic Gross
🇩🇪Großhansdorf, Schleswig-Holstein, Germany
Gemeinschaftspraxis fuer Haematologie und Onkologie
🇩🇪Muenster, Germany
Medizinische Fakultät Mannheim Uni Heidelberg
🇩🇪Mannheim, Germany
Országos Korányi TBC és Pulmonológiai Intézet
ðŸ‡ðŸ‡ºBudapest, Hungary
CRO, IRCCS, Istituto Nazionale Tumori
🇮🇹Aviano, Pordenone, Italy
Azienda Policlinico Umberto I
🇮🇹Rome, Roma, Italy
Iov-Irccs
🇮🇹Padova, Italy
AOU S.Martino, IRCCS, IST-Istituto Nazionale Ricerca Sul Can
🇮🇹Genova, Italy
Ospedale Guglielmo da Saliceto, AUSL Piacenza
🇮🇹Piacenza, Italy
Istituti Fisioterapici Ospitalieri Regina Elena
🇮🇹Roma, Italy
Sint Antoniusziekenhuis, location Utrecht
🇳🇱Utrecht, Netherlands
Ziekenhuis St Jansdal
🇳🇱Harderwijk, Gelderland, Netherlands
Ziekenhuis Assen
🇳🇱Assen, Drenthe, Netherlands
Isala Klinieken Zwolle
🇳🇱Zwolle, Overijssel, Netherlands
Gelre Ziekenhuis Zutphen
🇳🇱Zutphen, Gelderland, Netherlands
Uniwersytecki Szpital Kliniczny w Bialymstoku
🇵🇱Bialystok, Podlaskie, Poland
Wielkopolskie Centrum Pulmonologii i Torakochirurgii
🇵🇱Poznan, Wielkopolskie, Poland
Szpital Chorob Pluc im. Sw. Jozefa w Pilchowicach
🇵🇱Pilchowice, Poland
Institutul Oncologic "Prof.Dr.I.Chiricuta" Cluj Napoca
🇷🇴Cluj-Napoca, Romania
Clinical Centre of Serbia
🇷🇸Beograd, Belgrade, Serbia
Synta Pharmaceuticals Investigational Site
🇬🇧Southampton, United Kingdom
Szpital Specjalistyczny
🇵🇱Prabuty, Poland
Institute for pulmonary diseases of Vojvodine
🇷🇸Sremska Kamenica, Serbia
Spitalul Clinic Coltea
🇷🇴Bucuresti, Romania
Oncomed
🇷🇴Timisoara, Romania
Univerzitetna klinika za pljucne bolesti in alergijo Golnik
🇸🇮Golnik, Slovenia
Onkoloski institut Ljubljana
🇸🇮Ljubljana, Slovenia
Xerencia de Xestión Integrada A Coruña Hospital Teresa Herrera
🇪🇸La Coruña, A Coruña, Spain
Clinical Centre Nis
🇷🇸Nis, Nišavski okrug, Serbia
Onkologikoa
🇪🇸San Sebastian, Guipuzcoa, Spain
H.U. Reina SofÃa
🇪🇸Córdoba, Spain
H.U. Vall d'Hebrón
🇪🇸Barcelona, Spain
F. Jiménez Diaz
🇪🇸Madrid, Spain
Hospital Universitari Germans Trias i Pujol
🇪🇸Badalona, Spain
Hospital Universitari i Politecnic La Fe
🇪🇸Valencia, Spain
Hospital Universitario Virgen del RocÃo
🇪🇸Sevilla, Spain
H. Son Llà tzer
🇪🇸Palma de Mallorca, Baleares, Spain
Hospital Universitario Ramón y Cajal
🇪🇸Madrid, Spain
Klinikum Bogenhausen
🇩🇪Muenchen, Bayern, Germany
Kliniken der Stadt Köln gGmbH
🇩🇪Köln, Nordrhein-Westfalen, Germany
Johann Wolfgang Goethe University Clinic Frankfurt
🇩🇪Frankfurt, Hessen, Germany
Fejér Megyei Szent György Egyetemi Oktató Kórház
ðŸ‡ðŸ‡ºSzékesfehérvár, Fejér, Hungary
Eastern Connecticut Hematology Associates
🇺🇸Norwich, Connecticut, United States
Arizona Clinical Research Center, Inc.
🇺🇸Tucson, Arizona, United States
City of Hope Comprehensive Breast Cancer Center
🇺🇸Duarte, California, United States
UC San Diego Moores Cancer Center
🇺🇸La Jolla, California, United States
Santa Barbara Hematology Oncology Medical Group, Inc.
🇺🇸Santa Barbara, California, United States
Lynn Cancer Institute Center for Hematology Oncology
🇺🇸Boca Raton, Florida, United States
Halifax Health - Medical Center
🇺🇸Daytona Beach, Florida, United States
Cancer Care Specialists of Central Illinois, S.C.
🇺🇸Decatur, Illinois, United States
Frauenshuh Cancer Center
🇺🇸Saint Louis Park, Minnesota, United States
Sparrow Regional Cancer Center
🇺🇸Lansing, Michigan, United States
North Shore Hematology Oncology Associates
🇺🇸East Setauket, New York, United States
Guthrie Medical Group, PC
🇺🇸Sayre, Pennsylvania, United States
Texas Oncology, P.A.
🇺🇸Beaumont, Texas, United States
Joe Arrington Cancer Research and Treatment Center
🇺🇸Lubbock, Texas, United States
Cancer Care Northwest
🇺🇸Spokane Valley, Washington, United States
Houston Methodist Hospital Research Institute
🇺🇸Houston, Texas, United States
Texas Oncology - Sherman
🇺🇸Sherman, Texas, United States
Green Bay Oncology
🇺🇸Green Bay, Wisconsin, United States
Landesklinikum Krems
🇦🇹Krems, Niederösterreich, Austria
Klinikum Wels-Grieskirchen
🇦🇹Wels, Oberösterreich, Austria
AZ Sint-Maarten - Campus Leopoldstraat
🇧🇪Mechelen, Antwerpen, Belgium
Elisabeth Linz Hospital
🇦🇹Linz, Austria
Cliniques Universitaire Saint-Luc
🇧🇪Bruxelles, Belgium
Fakultni nemocnice Ostrava
🇨🇿Ostrava - Poruba, Czech Republic
Vseobecna fakultni nemocnice v Praze
🇨🇿Prague, Czech Republic
Chu De Grenoble - Hopital Michallon
🇫🇷Grenoble, France
CHRU de Strasbourg
🇫🇷Strasbourg, France
J. Gutenberg Uni.Mainz
🇩🇪Mainz, Germany
Klinikum Kassel
🇩🇪Kassel, Hessen, Germany
Universitätsklinikum Leipzig [Pneumologie]
🇩🇪Leipzig, Sachsen, Germany
Klinikum Frankfurt An Der Oder
🇩🇪Frankfurt/Oder, Germany
Practice Laack
🇩🇪Hamburg, Germany
Unikl. Schleswig-Holstein - Lübeck
🇩🇪Lübeck, Germany
CRU Hungary Kft.
ðŸ‡ðŸ‡ºMiskolc, Hungary
Semmelweis Egyetem
ðŸ‡ðŸ‡ºBudapest, Hungary
Irccs Irst
🇮🇹Meldola, Forli, Italy
Békés Megyei Pándy Kálmán Kórház
ðŸ‡ðŸ‡ºGyula, Hungary
Azienda Ospedaliera San Gerardo
🇮🇹Monza, Lombardia, Italy
Ospedale S.Maria della Misericordia, AO di Perugia, Universi
🇮🇹Perugia, Italy
Borgo Roma, Policlinico G.Rossi, AOU Integrata Verona
🇮🇹Verona, Italy
Medica Pro Familia Sp. z o.o. S.K.A.
🇵🇱Krakow, Malopolskie, Poland
Wojewodzki Szpital Specjalistyczny im. M.Kopernika
🇵🇱Lodz, Lodzkie, Poland
Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy
🇵🇱Otwock, Mazowieckie, Poland
Centrum Onkologii - Instytut im. Marii Sklodowskiej - Curie
🇵🇱Warszawa, Mazowieckie, Poland
Medisprof
🇷🇴Cluj Napoca, Romania
Institute for Oncology and Radiology of Serbia
🇷🇸Belgrade, Serbia
Hospital de Mataró, Consorci Sanitari del Maresme
🇪🇸Mataró, Barcelona, Spain
Hospital Madrid Norte Sanchinarro
🇪🇸Madrid, Spain
University Of Chicago Medical Center
🇺🇸Chicago, Illinois, United States
Ev. Krankenhaus Bielefeld
🇩🇪Bielefeld, Germany
Cancer Care Associates Medical Group, Inc.
🇺🇸Redondo Beach, California, United States
MVZ Äerzteforum Seestraße
🇩🇪Berlin, Germany
St. Louis Cancer Care, LLP - North County
🇺🇸Bridgeton, Missouri, United States
Novant Health Presbyterian Medical Center
🇺🇸Charlotte, North Carolina, United States
New Hanover Regional Medical Center - Zimmer Cancer Center
🇺🇸Wilmington, North Carolina, United States
Providence Regional Medical Center Everett
🇺🇸Everett, Washington, United States
Gesundheitszentrum Wetterau
🇩🇪Bad Nauheim, Hessen, Germany
Csongrád Megyei Önkormányzat Mellkasi Betegségek Szakkó
ðŸ‡ðŸ‡ºDeszk, Csongrád, Hungary
University of South Florida - H. Lee Moffitt
🇺🇸Tampa, Florida, United States
Rocky Mountain Cancer Center
🇺🇸Denver, Colorado, United States
UC Davis Medical Center - UC Davis Comprehensive Cancer
🇺🇸Sacramento, California, United States
The Center for Cancer and Blood Disorders (CCBD) - Bethesda
🇺🇸Bethesda, Maryland, United States
Novant Health Oncology Specialists
🇺🇸Winston-Salem, North Carolina, United States
Kaiser Permanente Northwest
🇺🇸Portland, Oregon, United States
Opca bolnica Pula
ðŸ‡ðŸ‡·Pula, Istarska županija, Croatia
NZOZ Med Polonia
🇵🇱Poznan, Wielkopolskie, Poland
Szpital Wojewodzki Zespolony
🇵🇱Elblag, Warminsko-mazurskie, Poland
Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc
🇵🇱Olsztyn, Poland
University Of North Carolina At Chapel Hill
🇺🇸Chapel Hill, North Carolina, United States
Clinique Saint-Pierre Ottignies
🇧🇪Ottignies, Brabant Wallon, Belgium
New Mexico Cancer Center
🇺🇸Albuquerque, New Mexico, United States
academisch ziekenhuis Maastricht
🇳🇱Maastricht, Limburg, Netherlands